Europe Cancer Vaccines Market Trends

Statistics for the 2023 & 2024 Europe Cancer Vaccines market trends, created by Mordor Intelligence™ Industry Reports. Europe Cancer Vaccines trend report includes a market forecast to 2029 and historical overview. Get a sample of this industry trends analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Trends of Europe Cancer Vaccines Industry

This section covers the major market trends shaping the Europe Cancer Vaccines Market according to our research experts:

Preventive Vaccines are Expected to a Hold Significant Market Share in the Treatment Method

Preventive vaccines or prophylactic vaccines are the vaccines intended to prevent cancer in healthy people. These vaccines work by preventing infectious agents that cause or contribute to the development of cancer. The European Medical Authority has approved Gardasil, Gardasil 9, and Cervarix vaccines to protect women from cervical cancer and other HPV-related cancers and pre-cancerous conditions.  

According to GLOBOCAN 2018, report, the number of incident cervical cancer cases in Europe were 61,072 cases and the total number of cancer cases was 56,9847. Therefore as cancer cases are increasing in Europe, the demand for cancer vaccines is expected to increase due to the rising incidence of cancer in the region. Therefore all these factors has helped in the overall market growth.

Europe cancer

Europe Cancer Vaccines Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)